ESMO 2023: Amivantamab plus lazertinib resulted in 30 percent reduction in risk of disease progression or death compared to osimertinib in patients with EGFR-mutated NSCLC

23 Oct 2023
ESMO 2023: Amivantamab plus lazertinib resulted in 30 percent reduction in risk of disease progression or death compared to osimertinib in patients with EGFR-mutated NSCLC

The results from the Phase 3 MARIPOSA study were announced today showing amivantamab-vmjw in combination with lazertinib compared to osimertinib resulted in a 30 percent reduction in the risk of disease progression or death (Hazard Ratio [HR]=0.70; 95 percent Confidence Interval [CI], 0.58–0.85; p value P<0.001) in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with either epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution. Results also showed a favourable trend in overall survival (OS) for amivantamab-vmjw and lazertinib in these patients compared to osimertinib (HR=0.80; 95 percent CI, 0.61–1.05; P=0.11) at a first interim analysis. 

"Despite advances in EGFR-mutated NSCLC treatment, novel targeted therapies and regimens are needed to address resistance and disease progression, which are nearly inevitable with current treatments," said Byoung Chul Cho,* M.D., Ph.D., medical oncologist and professor in the Division of Medical Oncology at Yonsei Cancer Center, Yonsei University College of Medicine in Seoul, Republic of Korea, and presenting author. "With the combination of amivantamab-vmjw and lazertinib in the MARIPOSA study, progression-free survival was significantly improved in patients with previously untreated EGFR-mutated NSCLC compared to osimertinib. These results support the potential of this amivantamab-vmjw combination to be a future standard of care."

At a median follow-up of 22 months, median progression-free survival (PFS) for amivantamab-vmjw and lazertinib was 23.7 months compared to 16.6 months for osimertinib (HR=0.70; 95 percent CI, 0.58–0.85; P<0.001). Other secondary endpoints showed consistent and clinically meaningful benefits for the combination of amivantamab-vmjw and lazertinib versus osimertinib across prespecified patient subgroups, including race, type of EGFR mutation, history of brain metastasis, and performance status. Lazertinib was included in the MARIPOSA study to determine its contribution to the combination with amivantamab-vmjw, and lazertinib monotherapy was shown to provide a clinically meaningful median PFS of 18.5 months (95 percent CI, 14.8–20.1).

The MARIPOSA study required all patients to have serial brain imaging with MRIs in order to detect or monitor brain metastases, a measure not implemented in most prior studies for EGFR-mutated NSCLC. The primary endpoint of PFS in MARIPOSA included these central nervous system (CNS) events detected by serial brain MRIs. Extracranial PFS, which may more closely approximate what would be seen in other trials, was also explored in MARIPOSA. The median PFS when censoring CNS-only first progressions was 27.5 months for the combination of amivantamab-vmjw and lazertinib, compared with 18.5 months for osimertinib (HR=0.68; 95 percent CI, 0.56–0.83; P<0.001). The median duration of response (DOR), or the length of time that a tumour continues to respond to treatment without the cancer growing or spreading, was significantly longer for patients receiving amivantamab-vmjw plus lazertinib compared to osimertinib, with a nine-month improvement in median DOR (25.8 vs. 16.8 months).

The safety profile of the combination of amivantamab-vmjw and lazertinib was consistent with the safety profiles of the individual treatments, with mostly Grade 1 or 2 adverse events (AEs). Toxicity was largely manageable with dose interruptions and reductions, along with supportive care measures commonly used in the treatment of patients with NSCLC. The most common Grade 3 or higher treatment-related AEs were rash and paronychia. Amivantamab-vmjw plus lazertinib had higher rates of EGFR- and MET-related AEs (hypoalbuminemia and peripheral oedema) and venous thromboembolism compared to osimertinib, with higher rates of diarrhoea being observed with osimertinib. The rate of discontinuation of all study treatments due to treatment-related AEs for the amivantamab-vmjw combination was 10 percent. The rate of interstitial lung disease (including pneumonitis) was less than three percent in both arms.

"Amivantamab-vmjw is a first-in-class bispecific antibody that targets major oncogenic driver pathways and, when combined with lazertinib, may lead to a more complete and synergistic response against the tumour," said Peter Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology, Janssen Research & Development, LLC. "The prolonged duration of progression-free survival and favourable trend in overall survival observed in the MARIPOSA study shows the potential of amivantamab-vmjw in combination with lazertinib to transform first-line treatment in EGFR-mutated NSCLC."  

Amivantamab-vmjw is a bispecific antibody targeting EGFR and MET with immune cell-directing activity, and in the MARIPOSA study, was combined with lazertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI), to treat patients with locally advanced or metastatic EGFR-mutated NSCLC. In the study, 1,074 patients were randomised to receive treatment with amivantamab-vmjw plus lazertinib, osimertinib alone or lazertinib alone. The primary endpoint was PFS following treatment with amivantamab-vmjw plus lazertinib compared to osimertinib as assessed by blinded independent central review (BICR) according to RECIST v1. Secondary endpoints included OS, objective response rate (ORR), DOR and intracranial PFS.

Results from MARIPOSA will support future planned health authority submissions.

Source: Janssen Pharmaceutical Companies of Johnson & Johnson